May 22, 2021

Antibody cocktail treatment given to Trump shows success against COVID-19

The antibody cocktail treatment against the coronavirus, which was given to then-president Donald Trump last year, is showing success against COVID-19, foreign media reported.

The medical agencies have said the Interim results showed that the REGN-COV2 antibody cocktail significantly reduces viral load in patients with SARS-CoV-2 virus and reduces Covid-19-related medical contacts.

The treatment known as REGN-COV2, which works by using two antibodies made to act like human antibodies in the immune system and attack the spike protein of the virus, has been approved by the government, the Federal Agency for Medicines and Health Products (FAMHP) has announced.

Experts expect the antibody cocktail drug for Covid-19 developed by pharmaceutical giants Roche and Regeneron to work effectively in home-isolated mild to moderate patients who are at high risk of developing severe illness. The therapy has been granted emergency use authorization in India a couple of days ago.

Named ‘REGN-COV2’, the drug is a cocktail of two monoclonal antibodies, Casirivimab and Imdevimab. It is projected to reduce hospitalization by 70%. The drug was tried by former US president Trump after he developed Covid-19 last year.

The therapy is also being looked at something that would help those whose vaccine barrier the virus has breached. It is also expected to be effective on children above 12 years (having body weight more than 40 kg) during the projected third wave when the younger poulation is likely to be at greater risk of contracting the infection.

Researchers in the western world are strongly pushing for yet another combination of monoclonal antibodies, Eli Lilly’s Bamlanivimab and Etesivimab, which have a strong data outcome on Covid patients. In March, it received US FDA approval as a potential therapy against variants of SARS-COV2.

A triple combination drug — repurposed Interferon Beta-1b with Lopinavir-Ritonavir and Ribavirin — is also projected to help in reducing the viral load and symptoms. The study has found a place in the ‘The Lancet’.